The material contained on this Web site is provided for informational purposes only and does not constitute legal advice. The publication and receipt of any information contained on this Web site does not create an attorney-client relationship with Barash Law LLC or with any of our attorneys. Readers should not act upon any information on this site without seeking professional legal counsel. While the information on this Web site is maintained and periodically updated for accuracy, this information may contain omissions or errors for which we disclaim any and all liability.
Barash Law LLC does not collect identifying information from visitors to its Web site unless the information is provided by the visitor or the visitor's internet browser. We will only respond to direct inquiries, and will use information collected from internet browsers for the sole purpose of monitoring Web site usage. We do not share Web site data with outside third-parties. Barash Law LLC is not responsible for the privacy practices or content of any links to other Web sites contained in our Firm’s Web site.
If you have any questions or concerns regarding this Privacy Statement, please contact us at email@example.com
The solid-state structure of an active pharmaceutical ingredient (API) can profoundly affect its properties. Stability and solubility are functions of the solid-state structure of APIs. This seminar will introduce the science behind such solid forms and then discuss how solid forms are protected as valuable intellectual property. We will provide examples of how a solid-form patent strategy is integrated into life cycle management and drug repositioning, the nuts and bolts of obtaining such patents at the USPTO, and how the courts have viewed such patents over the past 15 years. Although the focus will be on US practice, elements of European practice will also be presented.
Remdesivir is the first approved therapy for COVID-19, having first received an Emergency Use Authorization and then finally full approval on October 22, 2020. As a fully approved drug, the FDA has provided the public with both regulatory exclusivity and patent information. In this presentation, we will review that information, discuss what it means, and relate that to typical strategies used by innovator companies to protect valuable assets.